學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Getein Biotech: Trade-Offs in Strategic Decision-Making under the Covid-19 Pandemic
內容大綱
As of the end of 2019, the point-of-care testing (POCT) products of Getein Biotech Inc., an important in vitro diagnostics (IVD) enterprise, had been successfully applied to the detection of many diseases, including cardiovascular diseases, inflammation, kidney diseases, and blood coagulation disorders. Its market share and output value were both among the highest in the industry. In addition to improving its core POCT products, Getein Biotech firmly grasped industry opportunities to accelerate expansion in key IVD segments and build a complete product system. However, with the impact of COVID-19 in 2020, the enterprise, unlike its competitors in this industry, failed to seize the opportunity of developing COVID-19 test kits. As a result, its profits fell sharply, and its competitive position in the industry faced huge challenges. At the beginning of 2021, due to uncertainties about the COVID-19 pandemic, the enterprise was forced to integrate its original resources and capabilities and adjust its development strategy in order to establish sustainable competitive advantages.